South San Francisco, CA (PRWEB) April 13, 2015
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to host its Research and Development Day on Tuesday, May 12, 2015. The event is scheduled to take place from 8:00 AM – 11:00 AM Eastern Time at the New York Grand Hyatt Hotel in New York, New York and will be simultaneously webcast. Representatives of Cytokinetics’ senior management team will be joined by expert clinicians to provide updates regarding the company’s discovery and development programs including recent progress, milestones and other commentary.
Those interested in attending in person should RSVP to investor(at)cytokinetics(dot)com by April 29th. In addition, parties may access the live video webcast of this presentation and accompanying slides by visiting the Investor Relations section of the Cytokinetics’ website at http://www.cytokinetics.com. The live audio of the forum will also be accessible by dialing either (866) 999-2985 (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 26007834. The webcast replay of the presentation will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website following the event. The replay will also be available via telephone from May 12, 2015 at 1:00 PM Eastern Time until May 26, 2015 by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (International) and typing in the passcode 26007834.
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics is developing tirasemtiv, a fast skeletal muscle activator, as a potential treatment for amyotrophic lateral sclerosis (ALS). Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at http://www.cytokinetics.com/.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics’ drug candidates and potential drug candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.
Joanna L. Goldstein
Manager, Investor Relations & Corporate Communications